Icon Plc (NASDAQ:ICLR) Receives $157.47 Average Target Price from Analysts

Icon Plc (NASDAQ:ICLR) has been assigned an average recommendation of “Hold” from the seventeen analysts that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $152.1333.

A number of analysts recently commented on the stock. Mizuho set a $216.00 target price on shares of Icon in a report on Friday, January 9th. Robert W. Baird set a $119.00 price target on shares of Icon in a research report on Friday, February 13th. Leerink Partners reaffirmed a “market perform” rating and issued a $105.00 price target on shares of Icon in a report on Thursday, February 12th. Barclays cut their price objective on Icon from $200.00 to $120.00 and set an “equal weight” rating for the company in a research report on Monday. Finally, BMO Capital Markets reissued a “market perform” rating and set a $100.00 price objective on shares of Icon in a research note on Thursday, February 12th.

Icon Price Performance

Shares of NASDAQ ICLR opened at $110.03 on Tuesday. Icon has a twelve month low of $66.57 and a twelve month high of $211.00. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $8.89 billion, a price-to-earnings ratio of 14.89, a PEG ratio of 2.75 and a beta of 1.36. The firm has a 50-day moving average of $150.65 and a two-hundred day moving average of $167.41.

Hedge Funds Weigh In On Icon

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Hsbc Holdings PLC purchased a new position in Icon in the 4th quarter worth about $2,012,000. River Road Asset Management LLC lifted its stake in Icon by 55.6% during the fourth quarter. River Road Asset Management LLC now owns 475,413 shares of the medical research company’s stock valued at $86,630,000 after buying an additional 169,860 shares in the last quarter. Investment Insight Wealth Management LLC acquired a new position in shares of Icon in the fourth quarter worth about $574,000. White Knight Strategic Wealth Advisors LLC increased its position in shares of Icon by 6.8% in the fourth quarter. White Knight Strategic Wealth Advisors LLC now owns 2,193 shares of the medical research company’s stock worth $400,000 after acquiring an additional 140 shares in the last quarter. Finally, Invesco Ltd. increased its position in shares of Icon by 9.6% in the fourth quarter. Invesco Ltd. now owns 3,756,896 shares of the medical research company’s stock worth $684,582,000 after acquiring an additional 329,266 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.